You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
ATP citrate lyase (ACL) inhibitor (IC50 = 0.13 μM for human recombinant ACL); blocks lipid synthesis (IC50 = 8 μM in HepG2 cells). Displays no cytotoxicity up to a concentration of 50 μM. Lowers plasma glucose and triglycerides in a mouse model of hyperlipidemia. Orally bioavailable.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 424.3. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||4.71 mL||23.57 mL||47.14 mL|
|2.5 mM||0.94 mL||4.71 mL||9.43 mL|
|5 mM||0.47 mL||2.36 mL||4.71 mL|
|25 mM||0.09 mL||0.47 mL||0.94 mL|
References are publications that support the biological activity of the product.
Li et al (2007) 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg.Med.Chem.Lett. 17 3208 PMID: 17383874
Ma et al (2009) A novel direct homogeneous assay for ATP citrate lyase. J.Lipid Res. 50 2131 PMID: 19286649
If you know of a relevant reference for BMS 303141, please let us know.
View Related Products by Product Action
Keywords: BMS 303141, BMS 303141 supplier, BMS303141, ATP, citrate, lyases, inhibits, inhibitors, plasma, glucose, triglycerides, orally, bioavailable, synthases, transferases, ACLY, Citrate, Lyase, 4609, Tocris Bioscience
2 Citations for BMS 303141
Citations are publications that use Tocris products. Selected citations for BMS 303141 include:
Namgaladze et al (2018) Polarization of Human Macrophages by Interleukin-4 Does Not Require ATP-Citrate Lyase. Front Immunol 9 2858 PMID: 30568658
Shah et al (2016) Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism. Oncotarget 7 43713 PMID: 27248322
Do you know of a great paper that uses BMS 303141 from Tocris? Please let us know.
Reviews for BMS 303141
There are currently no reviews for this product. Be the first to review BMS 303141 and earn rewards!
Have you used BMS 303141?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.